MiniMed Names David Segal Chief Medical Officer
The diabetes device maker tapped Segal, who brings more than 20 years of diabetes and digital health experience, as Robert Vigersky moves to emeritus status.
Updated on Nov. 4, 2026 in Diabetes
MiniMed has named David Segal, M.D., its chief medical officer. Robert Vigersky, M.D., who has served as CMO since 2019, will move to chief medical officer emeritus ahead of his planned retirement at the end of 2027.
Why it matters
The leadership change comes as MiniMed operates as an independent company following its separation from Medtronic and its March Nasdaq listing. Segal's background in diabetes care and remote monitoring positions the company's medical leadership around digital tools for people living with diabetes.
The announcement is a company-issued personnel notice, and the source does not provide independent verification of Segal's credentials. The filing does not address whether the transition will alter MiniMed's product development schedule.
The players
MiniMed
MiniMed is a diabetes technology company that became fully independent from Medtronic in October after a Nasdaq IPO, and that makes insulin pumps including the MiniMed Flex.
David Segal, M.D.
Segal is a diabetes care and digital health physician with more than 20 years of experience who was named MiniMed's chief medical officer.
Robert Vigersky, M.D.
Vigersky is an endocrinologist who served as MiniMed's chief medical officer since 2019 and has moved to emeritus status ahead of retirement.
Medtronic
Medtronic is a global medical technology company that retained about 90% ownership of MiniMed after the IPO before completing its separation in October.
The details
Segal previously served as medical director of innovation and remote monitoring care at Parkview Health's Mirro Center for Research and Innovation, where he helped establish a pediatric endocrinology service. He also established a diabetes and endocrinology practice in South Africa and co-founded Guidepost, a digital health company offering diabetes telecoaching services.
Timeline
2019: Vigersky became MiniMed's chief medical officer.
March 9, 2026: MiniMed closed its Nasdaq IPO, raising $560 million in gross proceeds.
October 15, 2026: MiniMed completed its separation from Medtronic and became a fully independent company.
End of 2027: Vigersky is scheduled to retire.
Roadmap
The MiniMed Flex, which received FDA clearance in March, is roughly half the size of the 780G pump cleared in 2023, marking a continued push toward smaller automated insulin delivery systems. The leadership appointment signals that MiniMed is positioning its clinical team around the company's next generation of diabetes technology.
The MiniMed Flex is controlled through a compatible smartphone app and uses the SmartGuard algorithm to adjust insulin delivery automatically based on glucose readings. People using insulin pumps may see the company's new medical leadership shape how future features are evaluated for real-world use.
The takeaway
Leadership changes at device makers often foreshadow shifts in product direction, so readers following diabetes technology can watch how MiniMed's new medical team approaches its smaller insulin pump lineup. Checking a device's FDA clearance status and compatibility details before a purchase or prescription change remains a practical step.
Further reading
Explore more Diabetes coverage for the latest on treatment technology and the companies building it.
